<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="125299">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01471340</url>
  </required_header>
  <id_info>
    <org_study_id>P06241</org_study_id>
    <secondary_id>2011-002142-13</secondary_id>
    <secondary_id>MK-0887A-202</secondary_id>
    <nct_id>NCT01471340</nct_id>
  </id_info>
  <brief_title>A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241 AM3)</brief_title>
  <acronym>SPIRO</acronym>
  <official_title>A 26-Week Randomized, Double-Blinded, Active Controlled Study Comparing the Safety of Mometasone Furoate/Formoterol Fumarate MDI Fixed Dose Combination Versus Mometasone Furoate MDI Monotherapy in Adolescents and Adults With Persistent Asthma (Protocol No. P06241 Also Known as P202)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the safety of DULERA. DULERA is a pressurized
      metered-dose inhaler (MDI) that contains two drugs combined, namely mometasone and
      formoterol in a single inhaler. Mometasone is an inhaled corticosteroid (ICS), which reduces
      the inflammation in the airways. Formoterol is a long-acting beta 2 agonist (LABA), which
      helps to relax the muscles of the airways in the lungs, making it easier to breathe. In
      combination, mometasone and formoterol are used for the treatment of asthma. This study will
      evaluate whether participants taking a LABA in combination with an ICS in a single inhaler
      have a different risk of having serious asthma events (hospitalization, intubation and
      death) compared to participants taking an ICS alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Amendments 2 and 3 are specific to Brazil; all other countries will enroll patients under
      Amendment 1.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time-to-first serious asthma outcomes (a composite endpoint defined as asthma-related: hospitalizations, intubations, and deaths)</measure>
    <time_frame>Baseline up to 26 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time-to-first asthma exacerbation</measure>
    <time_frame>Baseline up to 26 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">11745</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Mometasone Furoate/Formoterol MDI 200/10 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MF/F MDI 200/10 mcg twice daily (BID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mometasone Furoate/Formoterol MDI 400/10 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MF/F MDI 400/10 mcg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mometasone Furoate MDI 200 mcg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MF MDI 200 mcg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mometasone Furoate MDI 400 mcg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MF MDI 400 mcg BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mometasone Furoate/Formoterol MDI 100/5 mcg</intervention_name>
    <description>two inhalations twice daily (BID)</description>
    <arm_group_label>Mometasone Furoate/Formoterol MDI 200/10 mcg</arm_group_label>
    <other_name>SCH 418131 (MK-0887A); Dulera/Zenhale</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mometasone Furoate/Formoterol MDI 200/5 mcg</intervention_name>
    <description>two inhalations BID</description>
    <arm_group_label>Mometasone Furoate/Formoterol MDI 400/10 mcg</arm_group_label>
    <other_name>SCH 418131 (MK-0887A); Dulera/Zenhale</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mometasone Furoate MDI 100 mcg</intervention_name>
    <description>two inhalations BID</description>
    <arm_group_label>Mometasone Furoate MDI 200 mcg</arm_group_label>
    <other_name>SCH 032088</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mometasone Furoate MDI 200 mcg</intervention_name>
    <description>two inhalations BID</description>
    <arm_group_label>Mometasone Furoate MDI 400 mcg</arm_group_label>
    <other_name>SCH 032088</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albuterol 90 mcg /salbutamol 100 mcg HFA MDI</intervention_name>
    <description>use as needed for asthma symptoms</description>
    <arm_group_label>Mometasone Furoate/Formoterol MDI 200/10 mcg</arm_group_label>
    <arm_group_label>Mometasone Furoate/Formoterol MDI 400/10 mcg</arm_group_label>
    <arm_group_label>Mometasone Furoate MDI 200 mcg</arm_group_label>
    <arm_group_label>Mometasone Furoate MDI 400 mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone/prednisolone</intervention_name>
    <description>Oral prednisone/prednisolone used only as an emergency rescue medication at the discretion of the investigator</description>
    <arm_group_label>Mometasone Furoate/Formoterol MDI 200/10 mcg</arm_group_label>
    <arm_group_label>Mometasone Furoate/Formoterol MDI 400/10 mcg</arm_group_label>
    <arm_group_label>Mometasone Furoate MDI 200 mcg</arm_group_label>
    <arm_group_label>Mometasone Furoate MDI 400 mcg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Persistent asthma for at least 1-year

          -  Must use a daily asthma controller medication for at least 4 weeks prior to
             randomization, including an inhaled corticosteroid (ICS) with or without a
             long-acting beta agonist (LABA) or other adjunctive asthma therapy OR be using a
             leukotriene receptor antagonist (LTRA), xanthine or short acting beta agonist (SABA)
             as a monotherapy.

          -  Must be able to discontinue current asthma medication

          -  Must have a history of at least one asthma exacerbation in previous 4 to 52 weeks

        Exclusion Criteria:

          -  Unstable asthma

          -  Taking high dose ICS with or without other adjunctive therapy who have an Asthma
             Control Questionnaire 6 (ACQ6) total score â‰¥ 1.5

          -  Taking LTRA, xanthine or SABA monotherapy with an ACQ-6 total score &lt; 1.5
             (controlled)

          -  Chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), or other
             significant, non-asthmatic, lung disease

          -  Clinically significant abnormality, illness or disorder of any body or organ system

          -  Significant underlying cardiovascular condition which may contraindicate use of a
             beta-agonist.

          -  History of smoking greater than 10-pack years

          -  Had an asthma exacerbation within 4 weeks of the Baseline Visit

          -  Had more than 4 asthma exacerbations or 2 hospitalizations within 52 weeks of the
             randomization visit

          -  Known or suspected hypersensitivity or intolerance to corticosteroids, beta-2
             agonists, or any of the (inactive ingredients) excipients present in the medications
             used in this study

          -  Require the use of chronic systemic steroids, omalizumab, or other monoclonal or
             polyclonal antibodies

          -  Requires the use of beta-blockers

          -  History of life-threatening asthma, including an asthma episode that required
             intubation and/or was associated with hypercapnia requiring noninvasive ventilatory
             support

          -  Lactating, pregnant, or plans to become pregnant during the course of the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>China</country>
    <country>Colombia</country>
    <country>Croatia</country>
    <country>Czech Republic</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Guatemala</country>
    <country>Hungary</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Latvia</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 16, 2016</lastchanged_date>
  <firstreceived_date>November 10, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Mometasone Furoate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Albuterol</mesh_term>
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Mometasone Furoate, Formoterol Fumarate Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
